Skip to Content
Merck
All Photos(3)

Key Documents

MABN10

Sigma-Aldrich

Anti-Amyloid β Antibody, clone W0-2

clone WO2, from mouse

Synonym(s):

Alzheimer disease, Alzheimer disease amyloid protein, Cerebral vascular amyloid peptide, Protease nexin-II, amyloid beta (A4) precursor protein, amyloid beta A4 protein, amyloid beta precursor protein, beta-amyloid peptide, human mRNA for amyloid A4 prec

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

purified immunoglobulin

clone

WO2, monoclonal

species reactivity

mouse, human

technique(s)

ELISA: suitable
immunohistochemistry: suitable (paraffin)
western blot: suitable

isotype

IgG2aκ

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

human ... APP(351)

General description

The cerebral and vascular plaques associated with Alzheimer′s disease (AD) are mainly composed of amyloid beta peptides (Aβ). Aβ is derived from cleavage of the amyloid precursor protein (APP) and varies in length from 39 to 43 amino acids. Aβ [1-40], Aβ [1-42], and Aβ [1-43] peptides result from cleavage of APP after residues 40, 42, and 43, respectively. The cleavage takes place by gamma-secretase during the last APP processing step. Aβ [1-40], [1-42] and [1-43] peptides are major constituents of the plaques and tangles that occur in AD. These Amyloid beta antibodies and peptides have been developed as tools for elucidating the biology of AD.

Specificity

This antibody recognizes amino acid residues 4-10 of human Amyloid β.

Immunogen

Epitope: Amino acid residues 4-10
Human Amyloid β peptide

Application

Detect Amyloid β using this Anti-Amyloid β Antibody, clone W0-2 validated for use in WB, IH, ELISA.
Immunohistochemistry Analysis: 1:500 dilution from a previous lot detected Amyloid β in Alzheimer’s diseased hippocampus.
Research Category
Neuroscience
Research Sub Category
Neurodegenerative Diseases

Quality

Evaluated by Western Blot in human Alzheimer disease brain tissue lysate.

Western Blot Analysis: 0.5 µg/ml of this antibody detected Amyloid β in 10 µg of human Alzheimer diseased brain tissue lysate.

Target description

Calculated MW is 4 kDa This antibody can also show 120 and 105 kDa APP proteins, and ~45 kDa oligomers of amyloid proteins on our western blot of human Alzheimer diseased brain lysate.

Linkage

Replaces: MAB1561

Physical form

Format: Purified
Protein G Purified
Purified mouse monoclonal IgG2aκ in buffer containing 0.1 M Tris-Glycine (pH 7.4, 150 mM NaCl) with 0.05% sodium azide.

Storage and Stability

Stable for 1 year at 2-8°C from date of receipt.

Analysis Note

Control
Human Alzheimer diseased brain tissue lysate

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Johnny Habchi et al.
Science advances, 2(2), e1501244-e1501244 (2016-03-05)
The conversion of the β-amyloid (Aβ) peptide into pathogenic aggregates is linked to the onset and progression of Alzheimer's disease. Although this observation has prompted an extensive search for therapeutic agents to modulate the concentration of Aβ or inhibit its
Deficits in the miRNA-34a-regulated endogenous TREM2 phagocytosis sensor-receptor in Alzheimer's disease (AD); an update.
Bhattacharjee, S; Zhao, Y; Lukiw, WJ
Frontiers in Aging Neuroscience null
Isaak Beyer et al.
Chemistry (Weinheim an der Bergstrasse, Germany), 22(25), 8685-8693 (2016-05-12)
In addition to the prototypic amyloid-β (Aβ) peptides Aβ1-40 and Aβ1-42 , several Aβ variants differing in their amino and carboxy termini have been described. Synthetic availability of an Aβ variant is often the key to study its role under
Jens V Andersen et al.
Cell death & disease, 12(11), 954-954 (2021-10-18)
Alzheimer's disease (AD) is an unremitting neurodegenerative disorder characterized by cerebral amyloid-β (Aβ) accumulation and gradual decline in cognitive function. Changes in brain energy metabolism arise in the preclinical phase of AD, suggesting an important metabolic component of early AD
Jens V Andersen et al.
Neurobiology of disease, 148, 105198-105198 (2020-11-27)
Alzheimer's disease (AD) leads to cerebral accumulation of insoluble amyloid-β plaques causing synaptic dysfunction and neuronal death. Neurons rely on astrocyte-derived glutamine for replenishment of the amino acid neurotransmitter pools. Perturbations of astrocyte glutamine synthesis have been described in AD

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service